Literature DB >> 10980934

Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis.

J Franco1, K Saeian.   

Abstract

Primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) are chronic progressive cholestatic diseases that frequently lead to biliary cirrhosis. The exact pathogenesis of these diseases remains elusive but is likely immunologically based. Complications range from fatigue and pruritus to end-stage liver disease. The risk of developing hepatocellular carcinoma is low for patients with PBC, whereas cholangiocarcinoma is common in PSC and carries an ominous prognosis. Although ursodeoxycholic acid is effective in slowing the progression of PBC, no effective medical therapy exists for PSC. Liver transplantation is the only option for patients with end-stage liver disease and yields excellent long-term survival in both groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10980934     DOI: 10.1007/s11894-996-0006-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  47 in total

1.  Primary biliary cirrhosis: epidemiology helping the clinician.

Authors:  J V Metcalf; D Howel; O F James; R Bhopal
Journal:  BMJ       Date:  1996-05-11

2.  Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.

Authors:  J Ludwig; S S Barham; N F LaRusso; L R Elveback; R H Wiesner; J T McCall
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

Review 3.  The clinical expression of primary biliary cirrhosis.

Authors:  J Heathcote
Journal:  Semin Liver Dis       Date:  1997-02       Impact factor: 6.115

4.  A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.

Authors:  T A Knox; M M Kaplan
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

5.  Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation.

Authors:  S G Hubscher; E Elias; J A Buckels; A D Mayer; P McMaster; J M Neuberger
Journal:  J Hepatol       Date:  1993-06       Impact factor: 25.083

6.  Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups.

Authors:  E Christensen; D G Altman; J Neuberger; B L De Stavola; N Tygstrup; R Williams
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

7.  Association of primary sclerosing cholangitis with HLA-B8.

Authors:  R W Chapman; Z Varghese; R Gaul; G Patel; N Kokinon; S Sherlock
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

8.  Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid.

Authors:  K Kyokane; T Ichihara; M Horisawa; N Suzuki; S Ichihara; S Suga; A Nakao; K Morise
Journal:  Hepatogastroenterology       Date:  1994-10

9.  Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.

Authors:  R H Wiesner; P M Grambsch; E R Dickson; J Ludwig; R L MacCarty; E B Hunter; T R Fleming; L D Fisher; S J Beaver; N F LaRusso
Journal:  Hepatology       Date:  1989-10       Impact factor: 17.425

10.  Hepatocellular carcinoma in primary biliary cirrhosis: detection by alpha-fetoprotein estimation.

Authors:  W M Melia; P J Johnson; J Neuberger; S Zaman; B C Portmann; R Williams
Journal:  Gastroenterology       Date:  1984-09       Impact factor: 22.682

View more
  4 in total

1.  A nuclear receptor ligand down-regulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists.

Authors:  Daisuke Komichi; Susumu Tazuma; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

2.  The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.

Authors:  C R Martin; P G Blanco; J C Keach; J L Petz; M M Zaman; K R Bhaskar; J E Cluette-Brown; S Gautam; S Sheth; N H Afdhal; K D Lindor; S D Freedman
Journal:  Aliment Pharmacol Ther       Date:  2011-11-30       Impact factor: 8.171

3.  Flowcharts for the management of biliary tract and ampullary carcinomas.

Authors:  Shuichi Miyakawa; Shin Ishihara; Tadahiro Takada; Masaru Miyazaki; Kazuhiro Tsukada; Masato Nagino; Satoshi Kondo; Junji Furuse; Hiroya Saito; Toshio Tsuyuguchi; Fumio Kimura; Hideyuki Yoshitomi; Satoshi Nozawa; Masahiro Yoshida; Keita Wada; Hodaka Amano; Fumihiko Miura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-02-16

Review 4.  Risk factors for biliary tract and ampullary carcinomas and prophylactic surgery for these factors.

Authors:  Masaru Miyazaki; Tadahiro Takada; Shuichi Miyakawa; Kazuhiro Tsukada; Masato Nagino; Satoshi Kondo; Junji Furuse; Hiroya Saito; Toshio Tsuyuguchi; Kazuo Chijiiwa; Fumio Kimura; Hideyuki Yoshitomi; Satoshi Nozawa; Masahiro Yoshida; Keita Wada; Hodaka Amano; Fumihiko Miura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-02-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.